Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology, which will ultimately be commercialised by Janssen. The agreement was facilitated by Johnson & Johnson Innovation.
The collaboration leverages Evotec’s integrated discovery and development capabilities and manufacturing optimisation processes, including an option for the GMP manufacture of the immune-based therapies. Evotec will collaborate closely with Janssen during the pre-clinical R&D phase while Janssen will assume full responsibility for the clinical development and commercialisation.
Besides research funding, Evotec is entitled to an undisclosed upfront payment, success-based research and commercial milestones exceeding US$ 350 m as well as tiered royalties on products resulting from the collaboration.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are very excited about this collaboration with Janssen. Novel immune-based therapies with disease-relevant, targeted mechanisms are expected to benefit large number of patients. Evotec is committed to leading the way in transformational innovation to treat and ultimately cure diseases of high unmet need.”
Evotec completes acquisition of Central Glass Germany
Evotec SE announced that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed. As Evotec Drug Substance (Germany) GmbH (“Evotec DS”), the strategic transaction strengthens Evotec’s c ... more
Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse
Evotec SE officially launched the construction of its J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® Toulouse, France (EU), the second facility of its kind and the first one on European ground, will employ Just – Evotec Biologics’ flexible J.POD ... more
Evotec SE announced that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd. Going forward, Central Glass Germany GmbH will oper ... more
Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to all patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data an ... more
Evotec is a leading drug discovery and development company providing high quality integrated research services to its customers in the pharmaceutical and biotechnology industries. With its strategic research alliances, Evotec AG supports its partners in various indication fields with innova ... more
Alligator Bioscience to Receive USD 6 Million Milestone Payment from Janssen
Alligator Bioscience announced that a development milestone payment of USD 6 million has been triggered under the partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech, Inc. The milestone payment is for the partnership agreement to initiate a clinical combination study of A ... more
MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
MorphoSys AG announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular f ... more
Genmab achieves USD 45 million milestone
Genmab A/S announced it has achieved a USD 45 million milestone in its DARZALEX™ (daratumumab) collaboration with Janssen Biotech, Inc. The milestone payment was triggered by the first commercial sale of DARZALEX in the United States. "Today marks a significant moment in the history of Genm ... more
